Oramed Pharmaceuticals

Update in progress

ORMP (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Oramed Pharmaceuticals Inc. develops pharmaceutical solutions focused on the oral delivery of therapeutic proteins. Its lead program is ORMD-0801, an oral insulin capsule in Phase III trials for diabetes. The company has licensing agreements with Oravax Medical Inc. to commercialize oral COVID-19 vaccines. Founded in 2002, Oramed is headquartered in New York, New York.

Company score

Sentiment: 0.22; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.15; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqCM (NCM)
LocationUnited States
CEOMr. Nadav Kidron Esq.
Founded2002
Websiteoramed.com

Identifiers

ISINUS68403P2039
FIGIBBG000LRYR36
LEI5299006K52ZIIGQJ6R84
CUSIP68403P104
CIK0001176309